FHLC vs XLV

Key Takeaways

• Both FHLC and XLV provide U.S. healthcare sector exposure with identical 0.08% expense ratios, but FHLC offers broader diversification with 333 holdings versus XLV's 62.
• FHLC tracks the MSCI US IMI 25/50 Health Care Index, including small- and mid-cap stocks, while XLV follows the S&P Health Care Select Sector Index focused on large-cap S&P 500 constituents.
• Top holdings overlap significantly—LLY, JNJ, ABBV, UNH, MRK—but XLV allocates ~59% to its top 10 compared to FHLC's ~51%.
• XLV exhibits superior liquidity with average daily volume exceeding 12 million shares, ideal for institutional traders, versus FHLC's ~177,000 shares.
• FHLC's inclusion of smaller companies may enhance growth potential but introduces higher volatility; XLV prioritizes stability from mega-cap leaders.
• Both benefit from defensive sector traits, with recent capital flows favoring healthcare amid macroeconomic uncertainty.

Introduction

Healthcare ETFs like FHLC and XLV offer investors targeted exposure to a resilient sector known for steady demand amid aging populations and innovation in pharmaceuticals and biotech. These funds compete indirectly: FHLC provides comprehensive coverage across market caps, while XLV focuses on large-cap stability within the S&P 500. Their comparison is timely as healthcare attracts inflows during market rotations away from tech, driven by interest rate dynamics and policy clarity on drug pricing. Investors seeking sector allocation can weigh FHLC's diversification against XLV's liquidity and concentration in proven leaders, aiding decisions on risk-adjusted exposure in portfolios.

Fidelity MSCI Health Care Index ETF (FHLC) Overview

The Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed fund tracking the MSCI US IMI 25/50 Health Care Index, which includes large-, mid-, and small-cap U.S. healthcare companies subject to a 25/50 concentration cap (limiting the largest issuer to 25% and top five to 50% combined). Launched in 2013, it holds 333 stocks with approximately $2.9 billion in assets under management (AUM).

Top holdings include LLY (~13%), JNJ (~9%), ABBV (~6%), UNH (~5%), and MRK (~5%), comprising ~51% of assets. Sector allocation emphasizes health technology (~81%) and health services (~13%). The expense ratio is a low 0.08%, with market-cap weighting and quarterly rebalancing to maintain index fidelity. FHLC suits investors desiring broad healthcare diversification beyond mega-caps.

State Street Health Care Select Sector SPDR ETF (XLV) Overview

The State Street Health Care Select Sector SPDR ETF (XLV), one of the oldest sector ETFs since 1998, tracks the Health Care Select Sector Index—a benchmark of S&P 500 healthcare constituents in pharmaceuticals, biotech, equipment, providers, and services. It manages ~$37 billion in AUM with 62 holdings.

Leading positions are LLY (~15%), JNJ (~10%), ABBV (~7%), UNH (~7%), and MRK (~5%), accounting for ~59% of assets. Industry breakdown: pharmaceuticals (37%), health care providers & services (19%), biotechnology (18%), equipment & supplies (17%). At 0.08% expense ratio, it uses market-cap weighting with quarterly reviews. XLV appeals for its liquidity and focus on established large-caps.

Industry and Thematic Backdrop

The U.S. healthcare sector, encompassing pharmaceuticals, biotech, providers, and devices, remains defensive with inelastic demand from demographics and medical advancements. Recent catalysts include policy resolutions on drug pricing, boosting sentiment after 2025 uncertainties, alongside AI-driven drug discovery and capital flows—global healthcare ETFs saw record $6.8 billion inflows in late 2025. Macro drivers like moderating inflation and stable interest rates favor growth in innovative therapies, though risks persist from regulatory scrutiny, patent cliffs, and reimbursement pressures. Sector rotation amid geopolitical tensions positions healthcare as a relative safe haven.

Performance and Positioning Comparison

In recent market cycles, FHLC and XLV have mirrored broader healthcare trends, with FHLC occasionally edging out due to mid- and small-cap contributions during risk-on phases. Over multi-year periods, annualized returns hover similarly around 9%, reflecting shared exposure to top holdings' earnings cycles—e.g., obesity treatments from LLY and steady revenues from JNJ. XLV's large-cap tilt yields lower volatility (beta ~0.58), suiting conservative positioning, while FHLC captures upside from sector rotation into smaller innovators. Both exhibit resilience versus broader equities amid rate expectations and commodity shifts, though FHLC shows marginally higher beta to healthcare momentum.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes. Explore it today to enhance your ETF comparison and sector analysis.

Tickeron AI Verdict

Tickeron’s AI favors FHLC with moderate probability for investors prioritizing diversification and cost efficiency, given its broader holdings reducing single-stock risk while matching XLV's expense ratio and trend consistency. XLV edges for liquidity and lower volatility in large-cap momentum environments. Selection hinges on risk tolerance—FHLC for growth exposure, XLV for stability—neither as definitive advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations